On June 25, E-Healthcare Manager released the "Top 100 Chinese Pharmaceutical Innovation Enterprises" list, with Sino Biopharm (1177.HK) once again ranking third. Since the list was first published in 2019, Sino Biopharm has been ranked in the first tier for eight consecutive years, highlighting the group's strong R&D innovation capabilities and abundant innovative achievements. The list is compiled by E-Healthcare Manager based on Clarivate's Cortellis data intelligence platform, which covers all stages of the drug R&D lifecycle. It is derived from a "three-dimension, four-indicator" evaluation system after data screening, integration, and analysis. 

 

 

From June 26 to 27, the "2026 China Pharmaceutical Innovation 100 Conference" was held in Tianjin. Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, attended the conference and delivered a speech titled "Ecological Reconstruction, Global Leap: The Innovation Narrative of Sino Biopharm", recounting the group's innovation and development journey and demonstrating its confidence in comprehensive innovation upgrading and advancing toward an international pharmaceutical company. 

 

Intensive Landing of Innovative R&D Achievements

 

Mr. Tse Hsin pointed out that Sino Biopharm has always placed R&D innovation at the core of its strategy. Its R&D investment has consistently been at the forefront of the industry, the proportion of revenue from innovative products continues to rise, and it holds a leading position in the four therapeutic areas of oncology, liver disease/cardiovascular metabolism, respiratory/autoimmune, and surgery/analgesia. 

 

 

In recent years, Sino Biopharm's innovation pipeline has entered an intensive harvest period, with a strong start in 2026: the world's first-in-class dual-target JAK/ROCK inhibitor Rovadicitinib (Anxu^®) was approved in February, providing a new treatment option for patients with intermediate- or high-risk myelofibrosis; Chia Tai Tianqing's independently developed CDK2/4/6 inhibitor Culmerciclib (Saitanxin^®) added a first-line treatment indication for HR+/HER2- breast cancer; the world's first oral selective peripheral μ-opiate receptor antagonist Naldemedine (SYMPROIC^®) was successively approved for the treatment of opiate-induced constipation (OIC) in adults; recently, the world's first-in-class Ganan-class broad-spectrum anti-infective drug Peceleganan (Puyike^®) was also approved for marketing for the treatment of secondary wound infections in burns. 

 

In addition, several marketing applications submitted by the group have been included in priority review, and the clinical data of various products under development have shown impressive results, receiving widespread attention at academic conferences such as the American Association for Cancer Research (AACR) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting. 

 

AI Empowers the Entire Industry Chain to Improve Quality and Efficiency

 

Sino Biopharm is one of the first pharmaceutical companies in China to officially integrate AI assistants, empowering multiple core business scenarios such as drug R&D, clinical medicine, production and quality management, supply chain management, and marketing promotion, continuously enhancing the efficiency of the entire drug lifecycle. 

 

 

In the early research stage, the group has preliminarily explored and built an AI-driven drug design (AIDD) platform. Mr. Tse Hsin introduced that thanks to the application of AI, the group's annual number of Investigational New Drug (IND) applications has increased to 20-30, ranking among the top in the industry. In the clinical aspect, intelligent solutions such as AI medical review, AI medical coding, clinical monitoring intelligent agents, center investigation intelligent agents, and intelligence analysis intelligent agents have been successfully built and applied, significantly improving the efficiency and decision-making quality of each link. With AI assistance, the expression level of a certain monoclonal antibody increased by about 20%, production efficiency was significantly improved, and sales conversion rates and corporate operational efficiency were also comprehensively enhanced. 

 

Previously, Sino Biopharm's application as an independent pharmaceutical company and its selection for the third "AI Applications Star" (MINDS) project by the World Economic Forum also represent high recognition of the group's AI application capabilities by an authoritative international list. 

 

Multi-dimensional Cooperation Reconstructs the Innovation Ecosystem

 

In recent years, Sino Biopharm has built its global innovation map through a series of domestic and international collaborations as pivots. In his speech, Mr. Tse Hsin comprehensively introduced the group's diversified layout strategy—a multi-pronged approach including investment and M&A, out-licensing, R&D cooperation, and product in-licensing, forming a unique pattern of two-way empowerment both domestically and internationally. 

 

 

In July 2025, the company fully acquired LaNova Medicines, thereby gaining a world-leading antibody discovery and ADC technology platform, as well as several potential global first-in-class (FIC)/Best-in-class (BIC) products in crucial clinical stages, such as LM-302 (CLDN18.2 ADC) and LM-108 (a C-C chemokine receptor type 8 (CCR8) monoclonal antibody), solidifying its leading position in the field of immuno-oncology. In January 2026, the company fully acquired domestic small interfering RNA (siRNA) innovative drug company Hygieia for 1.2 billion RMB, completing its innovative drug layout for the next-generation foundational pipeline in the cardiovascular and cerebrovascular field, and expanding its footprint in major chronic disease areas such as weight loss/metabolism and neuropsychiatry. Mr. Tse Hsin pointed out that these acquisitions are not simple asset purchases but rather a process of internalizing external cutting-edge innovation into its own growth engine through strong integration capabilities, allowing R&D and sales to advance in parallel. 

 

In March 2026, Sino Biopharm reached an exclusive global licensing agreement with the multinational pharmaceutical company Sanofi for Rovadicitinib, marking international recognition of the company's full-chain R&D capabilities, from drug project initiation to production quality control. In May 2026, Chia Tai Tianqing reached an exclusive strategic cooperation with GlaxoSmithKline (GSK), in-licensing the global first-in-class antisense oligonucleotide drug Bepirovirsen, which is expected to benefit the large population of hepatitis B patients in China. Mr. Tse Hsin pointed out that GSK chose Chia Tai Tianqing precisely because of its well-established compliance system and market-leading position in the liver disease field. 

 

Regarding the overseas expansion in the pharmaceutical sector, Mr. Tse Hsin stated that the company is preparing to establish the Shanghai Biopharmaceutical Enterprises Going Global Association, primarily targeting the "Belt and Road" countries and Southeast Asian markets, to promote the establishment of mutually recognized standards between China and related countries. The group exports Chinese original research to the world while serving domestic patients, deeply embedding itself in the global pharmaceutical innovation value chain. 

 

Sino Biopharm will adhere to the path of innovative development, advancing toward becoming a world-class pharmaceutical company that integrates global innovation resources, continuously expanding its pipeline layout, enhancing R&D efficiency and quality, meeting more clinical needs, and benefiting patients worldwide.